Wednesday, March 03, 2021 8:45:10 AM
Maravai LifeSciences Holdings, Inc. is a life sciences company. The Company provides products that enables the development of drug therapies, diagnostics, vaccines and support research on human diseases. The Company's segments include Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment manufactures and sells products used in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). Its Biologics Safety Testing segment sells specialized analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. The Company's Protein Detection segment sells labeling and detection reagents for researchers in immunohistochemistry.
New York Yankees and Duke Basketball
Recent MRVI News
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 12:30:55 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2026 08:30:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:05:56 PM
- Maravai LifeSciences Reports First Quarter 2026 Financial Results • Business Wire • 05/07/2026 08:01:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/24/2026 08:29:27 PM
- Maravai LifeSciences To Host Earnings Conference Call on Thursday, May 7, 2026 • Business Wire • 04/20/2026 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 08:16:39 PM
- Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results • Business Wire • 02/25/2026 09:01:00 PM
- Maravai LifeSciences To Host Earnings Conference Call on Wednesday, February 25, 2026 • Business Wire • 02/09/2026 10:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2026 10:28:30 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/23/2025 08:00:12 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/19/2025 09:38:53 PM
- Maravai LifeSciences Announces November 2025 Investor Conference Schedule • Business Wire • 11/10/2025 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2025 09:21:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2025 09:03:24 PM
- Maravai LifeSciences Reports Third Quarter 2025 Financial Results • Business Wire • 11/06/2025 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2025 08:23:34 PM
- Maravai LifeSciences To Host Earnings Conference Call on Thursday, November 6, 2025 • Business Wire • 10/22/2025 08:01:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 10/17/2025 10:13:44 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2025 09:02:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/11/2025 08:06:51 PM
